经动脉化疗栓塞联合索拉非尼治疗不可切除肝细胞癌的安全性 - Suppr

Suppr

超能文献

Safety of transarterial chemoembolization plus sorafenib combination treatment in unresectable hepatocellular carcinoma.

作者信息

Sinakos Emmanouil, Dedes Ioannis, Papalavrentios Lavrentis, Drevelegas Antonios, Akriviadis Evangelos

出版信息

Scand J Gastroenterol. 2010 Apr;45(4):511-2. doi: 10.3109/00365521003628335.

DOI:10.3109/00365521003628335

PMID:20113152

Abstract

摘要

相似文献

Safety of transarterial chemoembolization plus sorafenib combination treatment in unresectable hepatocellular carcinoma.

Scand J Gastroenterol. 2010 Apr;45(4):511-2. doi: 10.3109/00365521003628335.

Major achievements in hepatocellular carcinoma.

Lancet. 2009 Feb 21;373(9664):614-6. doi: 10.1016/S0140-6736(09)60381-0.

TACE with or without systemic therapy?

J Hepatol. 2012 Jun;56(6):1224-5. doi: 10.1016/j.jhep.2012.02.011. Epub 2012 Mar 5.

Clinical value of continuous administration of sorafenib in combination with modified transarterial chemoembolization in patients with unresectable hepatocellular carcinoma.

Chin Med J (Engl). 2013 Jan;126(2):385-6.

Transarterial chemoembolization and sorafenib in patients with intermediate-stage hepatocellular carcinoma: time to enter routine clinical practice?

Future Oncol. 2015;11(17):2371-3. doi: 10.2217/FON.15.173. Epub 2015 Aug 13.

Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma.

J Hepatol. 2012 Jun;56(6):1336-42. doi: 10.1016/j.jhep.2012.01.006. Epub 2012 Feb 4.

Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794].

BMC Cancer. 2008 Nov 26;8:349. doi: 10.1186/1471-2407-8-349.

The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma.

Aliment Pharmacol Ther. 2011 Jul;34(2):205-13. doi: 10.1111/j.1365-2036.2011.04697.x. Epub 2011 May 23.

Sorafenib in combination with transarterial chemoembolization for the treatment of hepatocellular carcinoma.

Clin Adv Hematol Oncol. 2016 Aug;14(8):585-7.

Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study.

J Dig Dis. 2013 Apr;14(4):181-90. doi: 10.1111/1751-2980.12038.

引用本文的文献

The role of sorafenib in downsizing hepatocellular carcinoma prior to liver transplantation and in treating tumor recurrence.

Ann Gastroenterol. 2011;24(3):228-230.

Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study.

Oncologist. 2010;15(11):1198-204. doi: 10.1634/theoncologist.2010-0180. Epub 2010 Oct 29.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Safety of transarterial chemoembolization plus sorafenib combination treatment in unresectable hepatocellular carcinoma.

作者信息

Sinakos Emmanouil, Dedes Ioannis, Papalavrentios Lavrentis, Drevelegas Antonios, Akriviadis Evangelos

出版信息

Scand J Gastroenterol. 2010 Apr;45(4):511-2. doi: 10.3109/00365521003628335.

DOI:10.3109/00365521003628335

PMID:20113152

Abstract

摘要